AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

4 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

The Clinical Vector Core (CVC) is a leader in viral vector manufacturing at Children’s Hospital of Philadelphia and the University of Pennsylvania, in support of investigational new drug applications (IND) and clinical studies worldwide. Our proven success has resulted in more than 165 vector products for 31 unique clinical indications that have reached 736 patients since 2007.* Learn more about how our vector products have affected patients’ lives.

*As of October 2022

For best viewing capabilities, we recommend using Firefox, Chrome, Safari, or Microsoft Edge.

Key Metrics

Metrics as of August 2022

99

# of Study Sites

31

# of INDs

10

# of Countries

Patients & Sites

Product Distribution

Our vectors have been successful and impactful in the field of cell and gene therapy, including the first-ever gene therapies approved by the U.S. Food and Drug Administration Kymriah® (tisagenlecleucel) and Luxturna™ (voretigene neparvovec-rzyl).

The Clinical Vector Core’s team of experts supports early-phase studies with vector production that is affordable, is completed within a short timeframe, and offers flexibility — all with quality control and quality assurance compliant with current Good Manufacturing Practices (cGMP).

The Clinical Vector Core Sets the Standard

Graphic of a truck

Approved supplier of GMP-process comparable pharm/tox material and investigational products for the National Institutes of Health (2021-present).

Graphic of a checkmark

Compliant with U.S. FDA, Medicines and Healthcare Products Regulatory Agency (MHRA), and European Medicines Agency (EMA) GMP manufacturing regulations applicable to early phase clinical trials.

Graphic of test tubes

Suited to national and international projects from academia, industry, and government.

Our $35 million clinical adeno-associated virus (AAV) and lentiviral (LV) vector GMP manufacturing facility is situated within a world-renowned pediatric research campus and was among the International Society of Pharmaceutical Engineering (ISPE) 2021 Facility of the Year awardees, receiving an Honorable Mention for its strengths in integration, social impact, and future-looking design and capabilities.